Form 4: Cytek Biosciences' Chief Technology Officer Reports Stock Transactions
SEC Form 4
Ming Yan, Chief Technology Officer of Cytek Biosciences, reports the acquisition and disposal of common stock and restricted stock units on May 19, 2025, related to vesting of RSU awards.
Summary
- On May 19, 2025, Ming Yan, the Chief Technology Officer of Cytek Biosciences, engaged in transactions involving the company's common stock and restricted stock units (RSUs).
- These transactions included the acquisition of common stock through the vesting of RSUs and the disposal of common stock to cover tax withholding obligations.
- Specifically, Yan acquired 1,981, 4,908, 3,683, and 4,108 shares of common stock through RSU vesting.
- Simultaneously, Yan disposed of 588, 1,456, 1,093, and 1,219 shares of common stock to satisfy tax obligations at a price of $2.69 per share.
- Following these transactions, Yan directly owns 6,042,126 shares of Cytek Biosciences common stock and varying amounts of RSUs.
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions by an officer, with no inherent positive or negative implications for the company's performance.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the transactions of company insiders.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect routine executive compensation and stock ownership adjustments.
Key Dates
| Date | Description |
|---|---|
| 05/18/2022 | Initial vesting date for some of the RSU awards (4/48th of total shares). |
| 05/18/2023 | Initial vesting date for some of the RSU awards (2/48th of total shares). |
| 08/18/2023 | Subsequent vesting date for some of the RSU awards (3/48th of total shares). |
| 11/18/2023 | Subsequent vesting date for some of the RSU awards (3/48th of total shares). |
| 03/10/2024 | Subsequent vesting date for some of the RSU awards (4/48th of total shares). |
| 05/18/2024 | Initial vesting date for some of the RSU awards (2/48th of total shares). |
| 08/18/2024 | Subsequent vesting date for some of the RSU awards (3/48th of total shares). |
| 11/18/2024 | Subsequent vesting date for some of the RSU awards (3/48th of total shares). |
| 03/10/2025 | Subsequent vesting date for some of the RSU awards (4/48th of total shares). |
| 05/18/2025 | Initial vesting date for some of the RSU awards (2/48th of total shares). |
| 05/19/2025 | Date of the reported transactions: RSU vesting and tax obligation fulfillment. |
| 05/21/2025 | Date of the Form 4 filing. |
| 08/18/2025 | Subsequent vesting date for some of the RSU awards (3/48th of total shares). |
| 11/18/2025 | Subsequent vesting date for some of the RSU awards (3/48th of total shares). |
| 03/10/2026 | Subsequent vesting date for some of the RSU awards (4/48th of total shares). |
Keywords
Cytek Biosciences, CTKB, Ming Yan, Chief Technology Officer, Form 4, Stock Transactions, Restricted Stock Units, RSU, Beneficial Ownership, Vesting, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.